Developer docs
API playgroundTry for free, no card

Search company profiles

Aion Biosystems

Full company profile

uuid0008wxm

Namestring
Aion Biosystems
Legal namestring
AION Biosystems Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Aion Biosystems is a medical device company that develops and markets the TempShield, an FDA-cleared Class II wearable continuous temperature monitoring device. The skin-wearable patch provides 24/7 real-time body temperature tracking with up to 90 days of battery life per charge, transmitting data via Bluetooth to a companion mobile application (IDION Shield) and a clinician dashboard, with EMR integration. The device is primarily marketed to cancer patients undergoing chemotherapy, with secondary use cases in post-operative care, sepsis prevention, pediatrics, and long-term/skilled nursing facilities. The company sells through enterprise field sales to health systems and cancer centers, supplemented by channel partnerships (notably with care coordination platform Olio) and state-government investments such as the $2 million Florida deployment. Revenue is generated through hardware sales of the TempShield device plus recurring monitoring services that are reimbursable under CMS code 99454 for Remote Patient Monitoring.

Underlying the product is a proprietary wearable medical device platform developed by CTO Tom Blackadar (40 patents, 25+ years in wearable/medical devices) and a small engineering team. Clinical evidence cited by the company includes a 67% hospital prevention rate in a Trilogy Health Services program, a 90% reduction in cancer deaths in a Schenectady study, and ongoing programs with Ellis Medicine, Roswell Park Cancer Center, New York Cancer & Blood Specialists, and Florida Cancer Specialists. The company is headquartered in Lowell, Massachusetts (per its website), was founded in 2017, and operates as a privately held entity with 51-100 employees. FDA 510(k) clearance (K232010) was granted in August 2023, and the company has secured national distribution and is enrolling thousands of cancer patients as of 2025-2026.

Short descriptiontext

Aion Biosystems is a medical device company that develops and markets TempShield, an FDA-cleared Class II wearable for continuous temperature monitoring, primarily serving cancer patients and other at-risk populations through enterprise sales to health systems, cancer centers, and skilled nursing facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDarien, United States
HQ citystring
Darien
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote patient monitoring, continuous temperature monitoring, wearable medical devices, infection detection, oncology care
Industry2 codes
PRIMARYHLAHACAK
Continuous Temperature & Fever Monitoring (Wearable Thermometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Remote Patient Monitoring Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1TempShield Device and Monitoring Services
TypeHardware Sales
Description

Sale of FDA-cleared TempShield wearable device with associated monitoring services. Device is reimbursable under CMS code 99454 for Remote Patient Monitoring (RPM). Revenue generated from device sales and ongoing monitoring services billed through healthcare reimbursement channels.

aionbiosystems.com
2CMS Reimbursement (RPM)
TypeSubscription Recurring
Description

Reimbursable under CMS code 99454 for Remote Patient Monitoring services. Healthcare providers can bill for the monitoring service, creating recurring revenue opportunity aligned with device usage.

aionbiosystems.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1CMS Reimbursable RPM Code 99454
ModelOtherBilling cadencePay-as-you-go
Notes

Reimbursable under CMS code 99454 for Remote Patient Monitoring. Healthcare providers bill Medicare/Medicaid for monitoring services using the TempShield device.

aionbiosystems.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TempShield
Description

FDA-cleared continuous temperature monitoring wearable device for cancer patients and others at risk of infection. Provides 24/7 real-time temperature tracking for up to 90 days per charge.

aionbiosystems.com
+1 more record
Core offering1 text field

AION Biosystems develops and markets the FDA-cleared TempShield continuous temperature monitoring wearable device, an FDA Class II medical device that provides 24/7 real-time body temperature tracking for up to 90 days per charge. The device pairs with a mobile application and clinician dashboard via Bluetooth, with EMR integration, and is sold primarily to healthcare providers (cancer centers, health systems, long-term care facilities) with billing enabled under CMS reimbursement code 99454 for Remote Patient Monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 67% hospital prevention rate among monitored residents in Trilogy Health Services program
+4 more records
Product overview1 text field

AION Biosystems offers the TempShield/iTempShield continuous temperature monitoring wearable system as its primary product offering. The system consists of an FDA-cleared skin-wearable device paired with a mobile application (IDION Shield) and a dedicated clinician dashboard. The TempShield device monitors patients 24/7 for up to 90 days, transmitting real-time temperature data via Bluetooth to the mobile app, which integrates with EMR systems and provides alerts to clinicians through the dashboard. The product targets cancer patients, post-operative patients, and those in long-term care or skilled nursing facilities to enable early detection of infections before they escalate to sepsis or hospitalization.

Product and service1 record
1AION TempShield (formerly iTempShield)
CategoryContinuous Temperature Monitoring Wearable Device
Description

FDA-cleared Class II medical device wearable providing 24/7 continuous body temperature monitoring for up to 90 days per charge. Targets cancer patients on chemotherapy, post-operative patients, pediatric patients, and those at risk of sepsis, with Bluetooth connectivity, mobile app integration, and EMR compatibility for healthcare providers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Strategic partnership to integrate FDA-cleared TempShield wearable temperature monitor into Olio's post-discharge coordination and Safe Return workflows. The partnership addresses the critical post-discharge blind spot for patients transitioning from skilled nursing facilities, enabling earlier detection and intervention for infections before they escalate to hospital readmissions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

iRhythm's Zio long-term cardiac monitoring patch is an FDA-cleared wearable diagnostic used for continuous outpatient monitoring. It is a partial overlap peer that demonstrates the commercial model of FDA-cleared, reimbursable continuous-monitoring wearables in clinical use.

2Health Recovery Solutions
TypeEmerging player
Description

Health Recovery Solutions provides an RPM platform deployed across hospitals, SNFs, and home health. It targets post-discharge and chronic care use cases that overlap with Aion's TempShield SNF and post-acute positioning.

TypeBroad incumbent
Description

Masimo is a large incumbent in patient monitoring with a portfolio of continuous vital sign sensors, including the Radius VSM wearable platform. It competes with TempShield across hospital and post-acute care with broader product breadth and deeper sales coverage.

4VitalConnect
TypeDirect peer
Description

VitalConnect offers the VitalPatch wearable biosensor for continuous vital sign monitoring in hospital and remote settings. It targets similar clinical use cases around continuous monitoring of at-risk patients and competes for the same RPM and post-discharge monitoring contracts.

TypeDirect peer
Description

Empatica develops FDA-cleared wearable health monitors (EpiMonitor, Embrace) for continuous physiological monitoring. It serves clinical and research customers with wearable biosensors similar in form factor and clinical positioning to TempShield.

TypeDirect peer
Description

BioIntelliSense produces the BioSticker and BioButton continuous vital sign monitoring wearables for remote patient monitoring. It targets the same RPM market with FDA-cleared wearables and integrates with health system EMRs, directly competing for enterprise RPM contracts.

TypeDirect peer
Description

Embr Labs is the most direct peer: it builds temperature-based wearable technology for personal comfort and health. Notably, Aion's Lead Biomedical Engineer Kristen Warren was the first employee at Embr Labs, indicating deep category overlap in continuous temperature wearables.

TypeDirect peer
Description

Current Health offers an end-to-end RPM platform with a wearable continuous vital sign monitor and clinician dashboard, targeting hospital-at-home and post-discharge use cases. It competes directly with Aion for enterprise RPM contracts and integrates with EMRs.

TypeBroad incumbent
Description

Philips offers continuous wearable patient monitoring through its Biosensor BX and broader RPM portfolio integrated with the Philips enterprise care platform. It is a broad incumbent in continuous patient monitoring that competes for the same health system contracts.

TypeEmerging player
Description

Vivify Health provides an RPM platform with connected device kits and clinician dashboards for health systems and payers. It overlaps with Aion's go-to-market in post-discharge and chronic condition monitoring, particularly where bundled devices and dashboards are required.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aion Biosystems

Remote Patient Monitoring Devicesaionbiosystems.com

Aion Biosystems is a medical device company that develops and markets TempShield, an FDA-cleared Class II wearable for continuous temperature monitoring, primarily serving cancer patients and other at-risk populations through enterprise sales to health systems, cancer centers, and skilled nursing facilities.

What Aion Biosystems does

Aion Biosystems is a medical device company that develops and markets the TempShield, an FDA-cleared Class II wearable continuous temperature monitoring device. The skin-wearable patch provides 24/7 real-time body temperature tracking with up to 90 days of battery life per charge, transmitting data via Bluetooth to a companion mobile application (IDION Shield) and a clinician dashboard, with EMR integration. The device is primarily marketed to cancer patients undergoing chemotherapy, with secondary use cases in post-operative care, sepsis prevention, pediatrics, and long-term/skilled nursing facilities. The company sells through enterprise field sales to health systems and cancer centers, supplemented by channel partnerships (notably with care coordination platform Olio) and state-government investments such as the $2 million Florida deployment. Revenue is generated through hardware sales of the TempShield device plus recurring monitoring services that are reimbursable under CMS code 99454 for Remote Patient Monitoring.

Underlying the product is a proprietary wearable medical device platform developed by CTO Tom Blackadar (40 patents, 25+ years in wearable/medical devices) and a small engineering team. Clinical evidence cited by the company includes a 67% hospital prevention rate in a Trilogy Health Services program, a 90% reduction in cancer deaths in a Schenectady study, and ongoing programs with Ellis Medicine, Roswell Park Cancer Center, New York Cancer & Blood Specialists, and Florida Cancer Specialists. The company is headquartered in Lowell, Massachusetts (per its website), was founded in 2017, and operates as a privately held entity with 51-100 employees. FDA 510(k) clearance (K232010) was granted in August 2023, and the company has secured national distribution and is enrolling thousands of cancer patients as of 2025-2026.

Aion Biosystems firmographics

Firmographics
Name
Aion Biosystems
Legal name
AION Biosystems Inc.
Website
https://aionbiosystems.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Aion Biosystems is a medical device company that develops and markets TempShield, an FDA-cleared Class II wearable for continuous temperature monitoring, primarily serving cancer patients and other at-risk populations through enterprise sales to health systems, cancer centers, and skilled nursing facilities.
Ownership category
akta.pro rank

Aion Biosystems industry classification

Industry
Product category
Remote Patient Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAK
Continuous Temperature & Fever Monitoring (Wearable Thermometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Remote patient monitoring
  • Continuous temperature monitoring
  • Wearable medical devices
  • Infection detection
  • Oncology care

Where Aion Biosystems is headquartered

Location

Headquarters

HQ city
Darien
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aion Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. TempShield Device and Monitoring Services: Sale of FDA-cleared TempShield wearable device with associated monitoring services. Device is reimbursable under CMS code 99454 for Remote Patient Monitoring (RPM). Revenue generated from device sales and ongoing monitoring services billed through healthcare reimbursement channels.
  2. CMS Reimbursement (RPM): Reimbursable under CMS code 99454 for Remote Patient Monitoring services. Healthcare providers can bill for the monitoring service, creating recurring revenue opportunity aligned with device usage.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCMS Reimbursable RPM Code 99454

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Aion Biosystems product offering

Product offering

Core offering

AION Biosystems develops and markets the FDA-cleared TempShield continuous temperature monitoring wearable device, an FDA Class II medical device that provides 24/7 real-time body temperature tracking for up to 90 days per charge. The device pairs with a mobile application and clinician dashboard via Bluetooth, with EMR integration, and is sold primarily to healthcare providers (cancer centers, health systems, long-term care facilities) with billing enabled under CMS reimbursement code 99454 for Remote Patient Monitoring.

Product overview

AION Biosystems offers the TempShield/iTempShield continuous temperature monitoring wearable system as its primary product offering. The system consists of an FDA-cleared skin-wearable device paired with a mobile application (IDION Shield) and a dedicated clinician dashboard. The TempShield device monitors patients 24/7 for up to 90 days, transmitting real-time temperature data via Bluetooth to the mobile app, which integrates with EMR systems and provides alerts to clinicians through the dashboard. The product targets cancer patients, post-operative patients, and those in long-term care or skilled nursing facilities to enable early detection of infections before they escalate to sepsis or hospitalization.

Differentiator

Problem solved

Functional benefit

Brands

  • TempShield: FDA-cleared continuous temperature monitoring wearable device for cancer patients and others at risk of infection. Provides 24/7 real-time temperature tracking for up to 90 days per charge.
  • iTempShield

Products and services

  • AION TempShield (formerly iTempShield) FDA-cleared Class II medical device wearable providing 24/7 continuous body temperature monitoring for up to 90 days per charge. Targets cancer patients on chemotherapy, post-operative patients, pediatric patients, and those at risk of sepsis, with Bluetooth connectivity, mobile app integration, and EMR compatibility for healthcare providers.

Quantifiable outcome

  • 67% hospital prevention rate among monitored residents in Trilogy Health Services program
  • +4 more outcomes

Companies that use Aion Biosystems

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Aion Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature5 records

Aion Biosystems partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • OliocoreStrategic or Co-development Partner · 21 April 2026Strategic partnership to integrate FDA-cleared TempShield wearable temperature monitor into Olio's post-discharge coordination and Safe Return workflows. The partnership addresses the critical post-discharge blind spot for patients transitioning from skilled nursing facilities, enabling earlier detection and intervention for infections before they escalate to hospital readmissions.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Aion Biosystems competitors and assessment

Company assessment

Emerging players

  • iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch is an FDA-cleared wearable diagnostic used for continuous outpatient monitoring. It is a partial overlap peer that demonstrates the commercial model of FDA-cleared, reimbursable continuous-monitoring wearables in clinical use.
  • Health Recovery Solutions: Health Recovery Solutions provides an RPM platform deployed across hospitals, SNFs, and home health. It targets post-discharge and chronic care use cases that overlap with Aion's TempShield SNF and post-acute positioning.
  • Vivify Health: Vivify Health provides an RPM platform with connected device kits and clinician dashboards for health systems and payers. It overlaps with Aion's go-to-market in post-discharge and chronic condition monitoring, particularly where bundled devices and dashboards are required.

Broad incumbents

  • Masimo: Masimo is a large incumbent in patient monitoring with a portfolio of continuous vital sign sensors, including the Radius VSM wearable platform. It competes with TempShield across hospital and post-acute care with broader product breadth and deeper sales coverage.
  • Philips (Patient Monitoring): Philips offers continuous wearable patient monitoring through its Biosensor BX and broader RPM portfolio integrated with the Philips enterprise care platform. It is a broad incumbent in continuous patient monitoring that competes for the same health system contracts.

Direct peers

  • VitalConnect: VitalConnect offers the VitalPatch wearable biosensor for continuous vital sign monitoring in hospital and remote settings. It targets similar clinical use cases around continuous monitoring of at-risk patients and competes for the same RPM and post-discharge monitoring contracts.
  • Empatica: Empatica develops FDA-cleared wearable health monitors (EpiMonitor, Embrace) for continuous physiological monitoring. It serves clinical and research customers with wearable biosensors similar in form factor and clinical positioning to TempShield.
  • BioIntelliSense: BioIntelliSense produces the BioSticker and BioButton continuous vital sign monitoring wearables for remote patient monitoring. It targets the same RPM market with FDA-cleared wearables and integrates with health system EMRs, directly competing for enterprise RPM contracts.
  • Embr Labs: Embr Labs is the most direct peer: it builds temperature-based wearable technology for personal comfort and health. Notably, Aion's Lead Biomedical Engineer Kristen Warren was the first employee at Embr Labs, indicating deep category overlap in continuous temperature wearables.
  • Current Health (Best Buy Health): Current Health offers an end-to-end RPM platform with a wearable continuous vital sign monitor and clinician dashboard, targeting hospital-at-home and post-discharge use cases. It competes directly with Aion for enterprise RPM contracts and integrates with EMRs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aion Biosystems social profiles

Digital presence

Aion Biosystems compliance and trust

Trust signal

Compliance2 records

Aion Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aion Biosystems leadership team

Management profile

Number of profiles

Profiles12 records

Aion Biosystems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aion Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aion Biosystems

What does Aion Biosystems do?

AION Biosystems develops and markets the FDA-cleared TempShield continuous temperature monitoring wearable device, an FDA Class II medical device that provides 24/7 real-time body temperature tracking for up to 90 days per charge. The device pairs with a mobile application and clinician dashboard via Bluetooth, with EMR integration, and is sold primarily to healthcare providers (cancer centers, health systems, long-term care facilities) with billing enabled under CMS reimbursement code 99454 for Remote Patient Monitoring.

Is Aion Biosystems a public or private company?

Aion Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aion Biosystems founded?

Aion Biosystems was founded in 2017. It employs 11 to 50 people.

Where is Aion Biosystems based?

Aion Biosystems is headquartered in Darien, United States, in the North America region.

How does Aion Biosystems make money?

Two revenue lines are on record. TempShield Device and Monitoring Services are the primary driver. The others are CMS Reimbursement (RPM).

Who are Aion Biosystems's main competitors?

Emerging players on record are iRhythm Technologies, Health Recovery Solutions and Vivify Health. Broad incumbents are Masimo and Philips (Patient Monitoring). Direct peers are VitalConnect, Empatica, BioIntelliSense, Embr Labs and Current Health (Best Buy Health).

Does Aion Biosystems have an API?

No public API is recorded for Aion Biosystems.

What industry is Aion Biosystems in?

Aion Biosystems's product category is Remote Patient Monitoring Devices. Its primary akta.pro industry code is HLAHACAK, Continuous Temperature & Fever Monitoring (Wearable Thermometry), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAION Biosystems Recognized as Finalist for the Digital Health Hub Foundation - Digital Health & AI Awards 2026 at HLTHAION Biosystems was named a finalist for the Digital Health Hub Foundation's 2026 Digital Health & AI Awards at HLTH, in the Home, Hybrid & Remote Care – Rising Star category. The company's TempShield device provides continuous temperature monitoring for up to 90 days, taking 288 readings daily to flag early infection signs. The awards ceremony will be held on November 16 at HLTH USA in Las Vegas.EIN PresswireAION Biosystems Recognized as Finalist for the Digital Health Hub Foundation - Digital Health & AI Awards 2026 at HLTHAION Biosystems was named a finalist for the Digital Health Hub Foundation's 2026 Digital Health & AI Awards at HLTH. Its TempShield device continuously monitors body temperature for up to 90 days, taking 288 readings daily to alert care teams of early infection signs. The awards ceremony will be held on November 16 at HLTH USA in Las Vegas.AijournOlio and AION Biosystems Partner to Close the Post-Discharge Blind SpotOlio, a care coordination platform for post-acute and behavioral health networks, announced a strategic partnership with AION Biosystems to integrate the FDA-cleared TempShield wearable temperature monitor into Olio's post-discharge coordination and Safe Return workflows. The TempShield device, which monitors patients for up to 90 days after discharge from skilled nursing facilities, was associated with a 67% hospital prevention rate among monitored residents in a program with Trilogy Health Services, addressing a critical gap in clinical monitoring during care transitions. The partnership aims to enable earlier detection and intervention for infections before they escalate to hospital readmissions, as nursing home residents are seven times more likely to develop severe sepsis compared to non-residents.Business Wire BlogOlio and AION Biosystems Partner to Close the Post-Discharge Blind SpotOlio and AION Biosystems partnered to integrate TempShield, an FDA-cleared wearable, into skilled nursing facility discharge workflows for continuous infection monitoring. The device detects early temperature trends, and a Trilogy Health Services program reported a 67% hospital prevention rate among monitored residents.SecSEC FORM DAION Biosystems, Inc. filed a Form D with the SEC on April 9, 2024, announcing an exempt securities offering under Rule 506(b) with a total offering amount of $5 million. As of the filing date, the company had sold approximately $2.5 million of the securities to one investor.